Literature DB >> 28722638

Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control.

Evan M Bloch1, Sheila K West2, Kasubi Mabula3, Jerusha Weaver2, Zakayo Mrango4, Beatriz Munoz2, Thomas Lietman5, Christian Coles6.   

Abstract

Mass administration of azithromycin (MDA) is integral to trachoma control. Recent studies suggest that MDA may increase drug-resistant pathogens, yet findings from prior studies suggest little long-term impact on resistance. This disparity may be linked to differences in pre-MDA community-level resistance patterns. We describe carriage prevalence and antibiotic resistance patterns for Streptococcus pneumoniae (Spn) (nasopharyngeal swab collection), Staphylococcus aureus (SA) (nasopharyngeal swabs), and Escherichia coli (EC) (rectal swabs) in 1,047 children ages 1-59 months in a district with MDA cessation 4 years ago. Antibiotic susceptibility was evaluated by disk diffusion and Etest. The carriage rates for Spn, SA, and EC were 43.5% (455/1,047), 13.2% (138/1,047), and 61.7% (646/1,047), respectively. Resistance to AZM was observed in 14.3%, 29.0%, and 16.6% of the Spn, SA, and EC isolates, respectively. Spn resistance was variable (0-67%) by hamlet. Future analyses will assess the influence of pre-MDA antibiotic resistance patterns on those observed following MDA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28722638      PMCID: PMC5590597          DOI: 10.4269/ajtmh.17-0022

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Authors:  Gunnar Kahlmeter; Derek F J Brown; Fred W Goldstein; Alasdair P MacGowan; Johan W Mouton; Anders Osterlund; Arne Rodloff; Martin Steinbakk; Pavla Urbaskova; Alkiviadis Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

2.  Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.

Authors:  A M Fry; H C Jha; T M Lietman; J S P Chaudhary; R C Bhatta; J Elliott; T Hyde; A Schuchat; B Gaynor; S F Dowell
Journal:  Clin Infect Dis       Date:  2002-07-23       Impact factor: 9.079

3.  Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children.

Authors:  Christian L Coles; Joshua Levens; Jessica C Seidman; Harran Mkocha; Beatriz Munoz; Sheila West
Journal:  Pediatr Infect Dis J       Date:  2012-04       Impact factor: 2.129

4.  The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma.

Authors:  Sara Haug; Takele Lakew; Gabremaskal Habtemariam; Wondu Alemayehu; Vicky Cevallos; Zhaoxia Zhou; Jenafir House; Kathryn Ray; Travis Porco; Tina Rutar; Jeremy Keenan; Thomas M Lietman; Bruce D Gaynor
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

5.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.

Authors:  Jessica C Seidman; Christian L Coles; Ellen K Silbergeld; Joshua Levens; Harran Mkocha; Lashaunda B Johnson; Beatriz Muñoz; Sheila K West
Journal:  Int J Epidemiol       Date:  2014-03-21       Impact factor: 7.196

6.  Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.

Authors:  G C Gray; D C McPhate; M Leinonen; G H Cassell; E P Deperalta; S D Putnam; J A Karcher; M H Sawyer; A Laurila; J D Connor
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

7.  A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.

Authors:  A J Leach; T M Shelby-James; M Mayo; M Gratten; A C Laming; B J Currie; J D Mathews
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

8.  Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae.

Authors:  Sarah L Batt; Bambos M Charalambous; Anthony W Solomon; Charles Knirsch; Patrick A Massae; Salesia Safari; Noel E Sam; Dean Everett; David C W Mabey; Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.

Authors:  Christian L Coles; Kasubi Mabula; Jessica C Seidman; Joshua Levens; Harran Mkocha; Beatriz Munoz; Sayoki G Mfinanga; Sheila West
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey.

Authors:  Sheila K West; Beatriz Munoz; Jerusha Weaver; Zakayo Mrango; Laura Dize; Charlotte Gaydos; Thomas C Quinn; Diana L Martin
Journal:  PLoS Negl Trop Dis       Date:  2016-01-15
  10 in total
  11 in total

Review 1.  Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Authors:  Meraf A Wolle; Sheila K West
Journal:  Expert Rev Anti Infect Ther       Date:  2019-02-18       Impact factor: 5.091

2.  A Cross-Sectional Study of the Availability of Azithromycin in Local Pharmacies and Associated Antibiotic Resistance in Communities in Kilosa District, Tanzania.

Authors:  Derick Ansah; Jerusha Weaver; Beatriz Munoz; Evan M Bloch; Christian L Coles; Thomas Lietman; Sheila K West
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

Review 3.  Trachoma.

Authors:  Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré
Journal:  Nat Rev Dis Primers       Date:  2022-05-26       Impact factor: 52.329

Review 4.  Uses of mathematical modeling to estimate the impact of mass drug administration of antibiotics on antimicrobial resistance within and between communities.

Authors:  Scott W Olesen
Journal:  Infect Dis Poverty       Date:  2022-06-30       Impact factor: 10.485

5.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

6.  Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa.

Authors:  Jeremy D Keenan; Ahmed M Arzika; Ramatou Maliki; Nameywa Boubacar; Sanoussi Elh Adamou; Maria Moussa Ali; Catherine Cook; Elodie Lebas; Ying Lin; Kathryn J Ray; Kieran S O'Brien; Thuy Doan; Catherine E Oldenburg; E Kelly Callahan; Paul M Emerson; Travis C Porco; Thomas M Lietman
Journal:  N Engl J Med       Date:  2019-06-06       Impact factor: 91.245

7.  Short-term increase in the carriage of azithromycin-resistant Escherichia coli and Klebsiella pneumoniae in mothers and their newborns following intra-partum azithromycin: a post hoc analysis of a double-blind randomized trial.

Authors:  Pauline Getanda; Abdoulie Bojang; Bully Camara; Isatou Jagne-Cox; Effua Usuf; Benjamin P Howden; Umberto D'Alessandro; Christian Bottomley; Anna Roca
Journal:  JAC Antimicrob Resist       Date:  2021-01-27

8.  Biannual Treatment of Preschool Children with Single Dose Azithromycin to Reduce Mortality: Impact on Azithromycin Resistance in the MORDOR Trial in Tanzania.

Authors:  Evan M Bloch; Christian L Coles; Mabula Kasubi; Jerusha Weaver; Zakayo Mrango; Beatriz Munoz; Thomas M Lietman; Sheila K West
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

9.  Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin.

Authors:  Soumeya Hema-Ouangraoua; Issaka Zongo; Nongodo Firmin Kabore; Nikiema Frédéric; Rakiswende Serge Yerbanga; Halidou Tinto; Yves Daniel Compaore; Irene Kuepfer; Daniel Chandramohan; Brian Greenwood; Jean Bosco Ouedraogo
Journal:  Am J Trop Med Hyg       Date:  2020-06-04       Impact factor: 2.345

10.  Mass Azithromycin Distribution to Prevent Childhood Mortality: A Pooled Analysis of Cluster-Randomized Trials.

Authors:  Catherine E Oldenburg; Ahmed M Arzika; Abdou Amza; Teshome Gebre; Khumbo Kalua; Zakayo Mrango; Sun Y Cotter; Sheila K West; Robin L Bailey; Paul M Emerson; Kieran S O'Brien; Travis C Porco; Jeremy D Keenan; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.